Actually, anti-VEGF drugs have been widely used in the clinical treatment of neovascular ocular diseases such as PDR, wet AMD, etc. However, their efficacy is limited, and long-term sustainability still faces challenges. The gene discussed is VEGFA; the disease is wet macular degeneration.